Weight-Based Dosing of Rifabutin for Tuberculosis Treatment
For adults with tuberculosis, rifabutin should be dosed at 5 mg/kg daily (typically 300 mg), and intermittent dosing is not recommended for TB treatment. 1
Adult Dosing
The official ATS/CDC/IDSA guidelines specify rifabutin dosing for TB treatment as:
- Daily therapy: 5 mg/kg (typically 300 mg daily) 1
- Twice-weekly: Not recommended 1
- Thrice-weekly: Not recommended 1
This is consistent with the FDA labeling, which recommends 300 mg once daily as the standard dose 2. For patients experiencing gastrointestinal upset, the dose can be split to 150 mg twice daily with food 2.
Pediatric Dosing
For children, appropriate dosing is unknown and estimated at approximately 5 mg/kg daily 1. The guidelines explicitly state that "appropriate dosing for children is unknown" but provide an estimate of 5 mg/kg based on extrapolation from adult data.
Limited pediatric data from HIV-positive children with MAC (not TB) showed mean doses of 18.5 mg/kg for infants <1 year, 8.6 mg/kg for children 2-10 years, and 4.0 mg/kg for adolescents 14-16 years, though there is no evidence that doses >5 mg/kg daily are useful 2.
Critical Dosing Adjustments
Drug Interactions
Rifabutin requires significant dose reduction when co-administered with certain antiretrovirals 1:
- With protease inhibitors or NNRTIs: Dose may need adjustment 1
- With ritonavir-boosted regimens: Reduce dose by at least 75% (maximum 150 mg every other day or three times weekly) 2
Renal Impairment
- Severe renal impairment (CrCl <30 mL/min): Consider reducing dose by 50% 2
- Mild to moderate renal impairment: No adjustment needed 2
Hepatic Impairment
- Mild hepatic impairment: No dose modification required 2
- Moderate to severe hepatic impairment: Pharmacokinetics unknown 2
Key Clinical Caveats
Rifabutin is primarily used as a substitute for rifampin in TB treatment when rifampin cannot be used (typically due to drug interactions with antiretrovirals). It is not a first-line agent for TB treatment.
The guidelines note that dosing should be based on actual weight in non-obese patients 1. For obese patients (>20% above ideal body weight), consider dosing based on ideal body weight or modified ideal body weight, with therapeutic drug monitoring if available 1.
Monitor closely for adverse effects including uveitis, which can occur particularly with higher doses or drug interactions 2. The typical 300 mg daily dose is generally well-tolerated when used appropriately.